Management of Neutropenic Fever

Evaluation and Management

• For patients with neutropenic fever (neutrophil count ≤500 cells/mm³ or ≤1000 cells/mm³ with predicted decrease to ≤500 cells/mm³), the American Society of Clinical Oncology recommends initiating empiric antibiotic therapy promptly, with options including cefepime, ceftazidime, imipenem, or meropenem 1, 2
• Blood cultures and other appropriate cultures should be obtained before starting antibiotics whenever possible, as recommended by the American Society of Clinical Oncology 3
• The Infectious Diseases Society of America suggests choosing empiric therapy with one of the following agents: cefepime, ceftazidime, imipenem, or meropenem, with an alternative regimen being aminoglycoside plus antipseudomonal penicillin, cephalosporin, or carbapenem 2
• Vancomycin should only be added if specific criteria for its use are met (suspected catheter-related infection, known colonization with resistant gram-positive organisms, etc.), as recommended by the Infectious Diseases Society of America 2
• If a patient becomes afebrile within 3-5 days and an etiologic agent is identified, therapy should be adjusted to the most appropriate drug(s), according to the American Society of Clinical Oncology 2
• For patients who remain febrile at 48 hours, the American Society of Clinical Oncology recommends continuing initial antibacterial therapy if clinically stable, or broadening antimicrobial coverage and seeking advice from an infectious disease specialist or clinical microbiologist if clinically unstable 1, 4
• Consideration of antifungal therapy is recommended if fever persists beyond 4-6 days, as suggested by the American Society of Clinical Oncology 1, 4
• Antibiotics can be discontinued if the neutrophil count is ≥0.5 × 10⁹/L, the patient is asymptomatic, has been afebrile for 48 hours, and blood cultures are negative, according to the American Society of Clinical Oncology 4
• In cases where the neutrophil count is <0.5 × 10⁹/L but the patient has been afebrile for 5-7 days without complications, antibiotics can be discontinued except in high-risk cases, as recommended by the American Society of Clinical Oncology 4